Form 8-K - Current report:
SEC Accession No. 0001193125-25-269652
Filing Date
2025-11-06
Accepted
2025-11-06 16:23:30
Documents
11
Period of Report
2025-11-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K okur-20251106.htm   iXBRL 8-K 50933
2 EX-1.1 okur-ex1_1.htm EX-1.1 452007
  Complete submission text file 0001193125-25-269652.txt   684789

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT okur-20251106.xsd EX-101.SCH 24879
13 EXTRACTED XBRL INSTANCE DOCUMENT okur-20251106_htm.xml XML 4722
Mailing Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301
Business Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301 (720) 307-2892
OnKure Therapeutics, Inc. (Filer) CIK: 0001637715 (see all company filings)

EIN.: 472309515 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40315 | Film No.: 251458728
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)